How signals steer CD8 immune cells toward long‑lasting memory or short‑lived killers
Molecular mechanisms of CD8 T cell fate decision instructed by cytokine signaling
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11260259
This work looks at how signals from infection or vaccines tell CD8 immune cells to become either long‑lasting memory cells or short‑lived killer cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11260259 on ClinicalTrials.gov |
What this research studies
When you get an infection or a vaccine, some CD8 T cells expand and most become short‑lived effectors while a few become memory cells that protect you later. This project examines how signals from the T cell receptor and cytokine receptors—especially IL‑2, but not IL‑15—work together to control the key transcription factor TCF‑1 and related gene programs. Researchers will use tools such as ATAC‑seq to map chromatin and identify transcriptional silencers at the Tcf7 gene and the sets of factors turned on during priming. The goal is to understand how early signaling events produce stable gene circuits that lock cells into effector or memory fates.
Who could benefit from this research
Good fit: This is primarily laboratory research with no clear patient enrollment listed, though people recently vaccinated or recovering from viral infections might be relevant for related sample donations or future clinical follow‑ups.
Not a fit: Patients seeking immediate changes to their care or those with conditions unrelated to CD8 T cell responses are unlikely to receive direct benefit from this basic research.
Why it matters
Potential benefit: If successful, these findings could help design vaccines or immunotherapies that produce stronger, longer‑lasting CD8 T cell memory and better protection against infections and cancer.
How similar studies have performed: Previous work shows TCF‑1 is important for forming CD8 memory, but the specific mechanism linking antigen and IL‑2 signals to epigenetic silencing at the Tcf7 locus is a novel and less‑tested idea.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EGAWA, TAKESHI — WASHINGTON UNIVERSITY
- Study coordinator: EGAWA, TAKESHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.